Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

Patricia LoRusso, Mark J. Ratain, Toshihiko Doi, Drew W. Rasco, Maja J.A. de Jonge, Victor Moreno, Benedito A. Carneiro, Lot A. Devriese, Adam Petrich*, Dimple Modi, Susan Morgan-Lappe, Silpa Nuthalapati, Monica Motwani, Martin Dunbar, Jaimee Glasgow, Bruno C. Medeiros, Emiliano Calvo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
24 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science